Fig. 3

Mean relative expression (compared to baseline) of a myosin heavy chains (MYH2A, MYH7, MYH8, MYH15), b myosin light chain kinase (MYLK) and skeletal muscle receptor tyrosine kinase (MUSK), c collagen type 1A1 (COL1A1), collagen type 1A2 (COL1A2) and collagen type 3A1 (COL3A1), d matrix metalloproteinase 13 (MMP13), e steroyl CoA desaturase (SCD) and lipoprotein lipase (LPL) and f β2-adrenergic receptor ((β2R) in skeletal muscle following oral administration of clenbuterol at the high dose protocol (Ventipulmin®;0.8 μg/kg, BID for 3 days, 1.6 μg/kg, BID for 3 days, 2.4 μg/kg, BID for 3 days and 3.2 μg/kg, BID for 21 days) to 6 racing fit Thoroughbred horses. ^arepresents changes that are significantly different (p <0.05) from baseline (pre-treatment), ^brepresents changes that are significantly different (p <0.05) from 48 h, ^crepresents changes that are significantly different (p <0.05) from day 7, ^drepresents changes that are significantly different (p <0.05) from day 14, ^erepresents changes that are significantly different (p <0.05) from day 28, ^frepresents changes that are significantly different (p <0.05) from day 35